ATB Therapeutics Names Mark Throsby as CEO

ATB Therapeutics, a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, has appointed Mark Throsby, PhD, as its Chief Executive Officer (CEO).

Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the company prepares to enter clinical development.

As part of this transition, co-founder Bertrand Magy will move into the role of Chief Operating Officer, and co-founder Max Houry will assume the role of Chief Business Officer.

Magy said: “From the beginning, ATB has been driven by a shared vision to create a new class of therapies with real patient impact. It has been an extraordinary scientific and entrepreneurial journey, and I am very proud of what we have accomplished so far. I look forward to continuing to work closely with Mark, Max, and the team as we enter this next chapter.”

Experience

Mark Throsby earned his PhD in Immunology from Monash University in Melbourne, Australia, and spent four years as a research fellow at CNRS in Paris. He began his industry career at Crucell (acquired by Johnson & Johnson), where he spent eight years in various roles, including Director of Antibody Discovery.

Prior to joining ATB, he served at Merus (acquired by Genmab) as COO and later CSO, where he played a key role in the development of the bispecific antibody therapeutics petosemtamab and zenocutuzumab. He is an expert in antibody engineering and immunology, with more than a dozen granted patents and > 50 peer-reviewed publications.

“I am honored to take on the role of CEO and excited to continue working closely with Bertrand, Max, the Board, and the broader ATB team as we advance our mission and bring antibodies closer to patients,” said Throsby.